Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Novo Ventures gives the nod to NodThera’s inflammatory disease innovations

Focused on targeting the source of chronic inflammation, NodThera has completed a $55m Series B round, which was led by Novo Ventures. What makes NodThera an attractive proposition to investors despite the ongoing pandemic?

Close
Close
Close

Go Top